Effectiveness of the Ad26.COV2.S (Johnson & Johnson) coronavirus disease 2019 (COVID-19) vaccine for preventing COVID-19 hospitalizations and progression to high disease severity in the United States
Clinical infectious diseases
Open Access Publication
Rights and Permissions
Nathaniel M Lewis, Wesley H Self, Manjusha Gaglani, Adit A Ginde, David J Douin, H Keipp Talbot, Jonathan D Casey, Nicholas M Mohr, Anne Zepeski, Shekhar A Ghamande, Tresa A McNeal, Nathan I Shapiro, Kevin W Gibbs, D Clark Files, David N Hager, Arber Shehu, Matthew E Prekker, Heidi L Erickson, Michelle N Gong, Amira Mohamed, Nicholas J Johnson, Vasisht Srinivasan, Jay S Steingrub, Ithan D Peltan, Samuel M Brown, Emily T Martin, Arnold S Monto, Akram Khan, Laurence W Busse, Caitlin C ten Lohuis, Abhijit Duggal, Jennifer G Wilson, Alexandra June Gordon, Nida Qadir, Steven Y Chang, Christopher Mallow, Carolina Rivas, Hilary M Babcock, Jennie H Kwon, Matthew C Exline, Adam S Lauring, Natasha Halasa, James D Chappell, Carlos G Grijalva, Todd W Rice, Jillian P Rhoads, Ian D Jones, William B Stubblefield, Adrienne Baughman, Kelsey N Womack, Christopher J Lindsell, Kimberly W Hart, Yuwei Zhu, Katherine Adams, Manish M Patel, Mark W Tenforde, IVY Network Collaborators, Effectiveness of the Ad26.COV2.S (Johnson & Johnson) Coronavirus Disease 2019 (COVID-19) Vaccine for Preventing COVID-19 Hospitalizations and Progression to High Disease Severity in the United States, Clinical Infectious Diseases, Volume 75, Issue Supplement_2, 1 October 2022, Pages S159–S166, https://doi.org/10.1093/cid/ciac439. Published by Oxford University Press on behalf of the Infectious Diseases Society of America 2022. This work is written by (a) US Government employee(s) and is in the public domain in the US.
Lewis, Nathaniel M; Babcock, Hilary M; Kwon, Jennie H; and et al., "Effectiveness of the Ad26.COV2.S (Johnson & Johnson) coronavirus disease 2019 (COVID-19) vaccine for preventing COVID-19 hospitalizations and progression to high disease severity in the United States." Clinical infectious diseases. 75, Supplement_2. S159 - S166. (2022).
Supplemental material is available for this article at publisher site.